Development of an inactivated COVID-19 vaccine
نویسندگان
چکیده
منابع مشابه
Side Effects of First and Second Doses of Inactivated COVID-19 Vaccine in Multiple Sclerosis
Background: It is currently recommended to vaccinate against SARS CoV-2 for people with multiple sclerosis (MS), but it is uncertain what effect it will have on people with MS (PwMS). Objectives: We aimed to compare the side effects of the first and second doses of the Sinopharm vaccine in PwMS. Materials & Methods: This descriptive-analytical follow-up study was conducted on PwMS patients...
متن کاملStrategies of vaccine production against COVID-19: when will an effective vaccine be produced?
There is a strong consensus globally that production of an effective vaccine against SARS-CoV-2 is likely the most effective approach to sustainably controlling the COVID-19 pandemic. An unprecedented research effort and global coordination has resulted in a rapid development of vaccine candidates and initiation of trials. In this paper, we review vaccine candidate against COVID-19 and also cha...
متن کاملEthical Issues in COVID-19 Vaccine Rollout
From the beginning of the COVID-19 pandemic, researchers aspired to produce an effective vaccine with appropriate efficacy and low side effects to mitigate the pandemic. It seems that vaccination is the only mean to save the world from this pandemic. In this article, we will review the ethical challenges of mass vaccination (focusing on the vaccine distribution and uptake), referring to the mai...
متن کاملThe Predictive Role of Vaccine Literacy and Vaccine Hesitancy on Acceptance of COVID-19 Vaccination
Background: Vaccination is preventive behavior, and vaccine literacy and hesitancy appear to influence vaccination. The aim of this study was to determine the role of vaccine literacy and hesitancy on the acceptance of the COVID-19 vaccine. Materials and Methods: In this cross-sectional study, 2185 residents over 18 years old in urban and rural health centers in three cities of Dashtestan, Dash...
متن کاملImmunogenicity and safety of an inactivated Rift Valley fever vaccine in a 19-year study.
An investigational, formalin-inactivated Rift Valley fever (RVF) vaccine, known as The Salk Institute-Government Services Division (TSI-GSD) 200 vaccine, was administered to 1860 at-risk subjects (5954 doses) between 1986 and 2004 as a three-dose primary series (days 0, 7, and 28) followed by booster doses as needed for declining titers. An initial positive serological response (PRNT(80)≥1:40) ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Translational and regulatory sciences
سال: 2021
ISSN: ['2434-4974']
DOI: https://doi.org/10.33611/trs.2021-022